Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.
The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.
Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.
The drug's novel molecular structure may result in fewer toxic adverse effects.
Darolutamide exerts its effects via competitive inhibition of androgen binding.
